Concas A, Santoro G, Mascia M P, Maciocco E, Dazzi L, Ongini E, Biggio G
Department of Experimental Biology, University of Cagliari, Italy.
J Pharmacol Exp Ther. 1993 Nov;267(2):844-51.
The possible relationship between A1 adenosine receptors and the gamma-aminobutyric acid (GABAA) receptor complex was evaluated in the mouse brain. We studied the effect of in vitro addition and in vivo administration of 2-chloro-N6-cyclopentyladenosine (CCPA), the most selective ligand for A1 receptors, on the biochemical parameters used currently to evaluate GABAergic function. In vitro, CCPA (0.01-100 microM) failed to modify [3H] GABA binding, [3H]flunitrazepam binding, t-[35S]butylbicyclophosphorothionate ([35S]TBPS) binding and muscimol-stimulated 36Cl- uptake. On the contrary, in vivo, CCPA (1.4-27.6 mumol/kg i.p.) increased [35S]TBPS binding in membranes from the cerebral cortex, hippocampus, striatum and substantia nigra, but not from the cerebellum, thalamus, hypothalamus and olfactory tubercle. The specific A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxantine (9.8 mumol/kg i.p.) abolished the effect of CCPA on [35S]TBPS binding, indicating that the action of this compound is mediated by its interaction with A1 receptors. Diazepam (1.7 mumol/kg i.p.), a positive modulator of GABAergic transmission, antagonized the increase of [35S]TBPS binding induced by CCPA. CCPA (2.8-8.3 mumol/kg i.p.) antagonized convulsions induced by isoniazid, an inhibitor of GABA synthesis, but neither antagonized nor potentiated isoniazid-induced increase of [35S]TBPS binding. CCPA (2.8-8.3 mumol/kg i.p.) antagonized the convulsions induced by pentylenetetrazol (398 mumol/kg i.p.), methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (50 mumol/kg i.p.) and bicuculline methiodide (9.8 mumol/kg i.p.). The results show that, in spite of its anticonvulsant activity, CCPA reduces the function of the GABA-coupled chloride channel function. This finding suggests that the anticonvulsant target sites are different from those involved in the action of CCPA on GABAA receptors.
在小鼠脑中评估了A1腺苷受体与γ-氨基丁酸(GABAA)受体复合物之间可能存在的关系。我们研究了A1受体最具选择性的配体2-氯-N6-环戊基腺苷(CCPA)的体外添加和体内给药对目前用于评估GABA能功能的生化参数的影响。在体外,CCPA(0.01 - 100微摩尔)未能改变[3H]GABA结合、[3H]氟硝西泮结合、t-[35S]丁基双环磷硫代酸盐([35S]TBPS)结合以及蝇蕈醇刺激的36Cl摄取。相反,在体内,CCPA(1.4 - 27.6微摩尔/千克腹腔注射)增加了大脑皮层、海马体、纹状体和黑质膜中的[35S]TBPS结合,但未增加小脑、丘脑、下丘脑和嗅结节膜中的[35S]TBPS结合。特异性A1受体拮抗剂8-环戊基-1,3-二丙基黄嘌呤(9.8微摩尔/千克腹腔注射)消除了CCPA对[35S]TBPS结合的影响,表明该化合物的作用是通过其与A1受体的相互作用介导的。地西泮(1.7微摩尔/千克腹腔注射),一种GABA能传递的正性调节剂,拮抗了CCPA诱导的[35S]TBPS结合增加。CCPA(2.8 - 8.3微摩尔/千克腹腔注射)拮抗了由异烟肼(一种GABA合成抑制剂)诱导的惊厥,但既未拮抗也未增强异烟肼诱导的[35S]TBPS结合增加。CCPA(2.8 - 8.3微摩尔/千克腹腔注射)拮抗了由戊四氮(398微摩尔/千克腹腔注射)、6,7-二甲氧基-4-乙基-β-咔啉-3-羧酸甲酯(50微摩尔/千克腹腔注射)和甲碘化荷包牡丹碱(9.8微摩尔/千克腹腔注射)诱导的惊厥。结果表明,尽管CCPA具有抗惊厥活性,但它降低了GABA偶联氯离子通道的功能。这一发现表明抗惊厥靶点与CCPA对GABAA受体作用所涉及的靶点不同。